Walid Abi-Saab

Chief Medical Officer Walid Abi-Saab sold 30,000 shares for $1,392,600 via scheduled 10b5-1 plan; stock down -41.5% from 52-week high.

Walid Abi-Saab, Chief Medical Officer at uniQure N.V., executed 2 separate sales totaling 30,000 shares for $1,392,600.00 on 2026-06-30 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-26. Post-transaction, he holds 148,235 shares of non-derivative stock, a reduction of 16.8% versus his pre-transaction position of 178,235 shares. The company trades at $41.81, which is -41.5% from its 52-week high of $71.50, while the blended sale price was $46.42. uniQure faces significant operational headwinds: latest quarterly revenue was $3,562,000.00, annual revenue growth was -40.6%, and full-year net income was negative at $-53,535,000.00. The sale is structured as a scheduled, non-discretionary transaction under 10b5-1 framework, not a discretionary market decision. Abi-Saab retains derivative holdings of 50,500 shares through stock options, preserving an ongoing equity interest in the company.

CMO Walid Abi-Saab exercises shares and sells 45,000 shares for ~$1.1M net, reducing stake by 10.5% as stock trades well below 52-week highs.

Walid Abi-Saab, Chief Medical Officer, exercised 25,000 shares and immediately sold 45,000 shares on the same day for a combined ~$1.1M, reducing his holdings by roughly one-tenth. This is his 6th and 7th open-market sale in the past three years—his pattern is consistently disposing shares when opportunities arise, with no open-market purchases in the same window. The sales themselves are not dramatic given the company's financial picture: uniQure is unprofitable with recent revenue declining sharply and net losses continuing to mount. The stock trades significantly below its 52-week high, having declined from the upper range over recent months. While a single executive selling during a period of financial strain is not unusual, the pattern of consistent dispositions—particularly a c-suite sale exceeding $1.1M in a single trading session—warrants attention to whether other officers or directors are also reducing exposure or whether this reflects normal equity management by a long-tenured medical officer with accumulated shares from compensation.